A composition or kit for determining the presence or absence of SARS-CoV-2 in a sample, said composition or kit comprising: (a) a first amplification oligomer combination comprising first and second SARS-CoV-2-specific amplification oligomers capable of amplifying a target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2-specific amplification oligomer comprises a first SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 12, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs, and (ii) wherein the second SARS-CoV-2-specific amplification oligomer comprises a second SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 13, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs; and (b) a second amplification oligomer combination comprising first and second SARS-CoV-2-specific amplification oligomers capable of amplifying a target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2-specific amplification oligomer comprises a first SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 15, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs, and (ii) wherein the second SARS-CoV-2-specific amplification oligomer comprises a second SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 16, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs. (a) a first amplification oligomer combination comprising first and second SARS-CoV-2-specific amplification oligomers capable of amplifying a target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2-specific amplification oligomer comprises a first SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 12, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs, and (ii) wherein the second SARS-CoV-2-specific amplification oligomer comprises a second SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 13, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs; and (i) wherein the first SARS-CoV-2-specific amplification oligomer comprises a first SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 12, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs, and (ii) wherein the second SARS-CoV-2-specific amplification oligomer comprises a second SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 13, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs; and (b) a second amplification oligomer combination comprising first and second SARS-CoV-2-specific amplification oligomers capable of amplifying a target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2-specific amplification oligomer comprises a first SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 15, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs, and (ii) wherein the second SARS-CoV-2-specific amplification oligomer comprises a second SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 16, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs. (i) wherein the first SARS-CoV-2-specific amplification oligomer comprises a first SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 15, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs, and (ii) wherein the second SARS-CoV-2-specific amplification oligomer comprises a second SARS-CoV-2-specific target-hybridizing sequence consisting of SEQ ID NO: 16, or an RNA equivalent or a DNA/RNA chimeric thereof and including from 0-7 nucleotide analogs.